Beyond INFUSE: Spine Community Searches For Answers, Alternatives

Medtronic's INFUSE bone morphogenetic protein is the only product in the musculoskeletal industry that has changed the bar in terms of bone healing, and it is under fire for complications related to off-label use. As regulators and payors crack down on INFUSE and hospitals restrict access to the product, surgeons are seeking alternatives and there are a number of companies lining up to fill the void

The medical technology arena is home to a number of “game-changing” technologies that initially took the industry by storm only to see their meteoric rise followed by a precipitous fall. The drug-eluting stent market is one example marked by an evolutionary (indeed some would say revolutionary) technology that was widely and broadly adopted for the first few years following market introduction, but took a hit when concerns surfaced about off-label use and potential complications. Even though those concerns were largely ameliorated, the market never did return to its initial fervor. More recently, studies suggesting implantable cardioverter defibrillators (ICDs) are often used outside of recommended guidelines and have thrown the cardiac rhythm management arena into a quandary as well. (See Also see "Cardiac Rhythm Management Market Faces Continued Challenges Ahead" - Medtech Insight, 1 August, 2011..) And now, a similar but potentially even more serious story is playing out in the musculoskeletal industry.

Only one product in the musculoskeletal arena has changed the bar in terms of bone healing and that is INFUSE,...

More from Archive

More from In Vivo

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

 
• By 

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.